Last ¥2,157 JPY
Change Today +11.00 / 0.51%
Volume 178.0K
4521 On Other Exchanges
Symbol
Exchange
Tokyo
As of 2:00 AM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

kaken pharmaceutical co ltd (4521) Snapshot

Open
¥2,138
Previous Close
¥2,146
Day High
¥2,172
Day Low
¥2,130
52 Week High
07/2/14 - ¥2,229
52 Week Low
10/8/13 - ¥1,426
Market Cap
209.0B
Average Volume 10 Days
231.7K
EPS TTM
¥114.18
Shares Outstanding
96.9M
EX-Date
09/26/14
P/E TM
18.9x
Dividend
¥54.00
Dividend Yield
2.23%
Current Stock Chart for KAKEN PHARMACEUTICAL CO LTD (4521)

Related News

No related news articles were found.

kaken pharmaceutical co ltd (4521) Related Businessweek News

No Related Businessweek News Found

kaken pharmaceutical co ltd (4521) Details

Kaken Pharmaceutical Co., Ltd. engages in the research, development, manufacture, sale, and export of pharmaceutical products, medical devices, agrochemicals, and animal health products in Japan. The company’s pharmaceutical and medical device products include Artz for the treatment of osteoarthritis of the knee, shoulder periarthritis, and knee joint pain accompanied by chronic rheumatoid arthritis; Procylin for the treatment of chronic artery occlusive diseases and pulmonary hypertension, ulcers, pains, and chills caused by arteriosclerosis obliterans and thromboangitis obliterans; and Adofeed, a plaster to treat pain and inflammation. It also offers Mentax for the treatment of superficial mycosis; Lipidil, a lipid-lowering agent; Fiblast Spray, a wound healing spray; Seprafilm, which creates a barrier between damaged tissue and the surrounding normal tissue. The company’s agrochemicals comprise Polyoxins, an active ingredient for use in fungicides; and Pentoxazone, a Protox inhibitor used to control broad leaves, barnyard grass, and monocholia in paddy fields. Its animal health products consist of Salinomycin, an anti-coccidial feed additive for chicken; and Colistin sulfate, a veterinary medicine or feed additive used to control diseases caused by gram-negative bacteria in poultry, swine, cattle, and other animals. The company’s products under development include KP-103, a products that has filed a new drug application for the treatment of onychomycosis; KCB-1D, a Phase III clinical trial product for the treatment of periodontitis; KCB-1B that has completed Phase II clinical trial for the treatment of bone fractures; TRK-100STP, a Phase II clinical trial product for the treatment of lumbar spinal canal stenosis; and SI-657 that is preparing for Phase III clinical trial for the treatment of Enthesopathy. It also owns and rents commercial facility. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.

Founded in 1917

kaken pharmaceutical co ltd (4521) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

kaken pharmaceutical co ltd (4521) Key Developments

Kaken Pharmaceutical Co. Ltd., Annual General Meeting, Jun 27, 2014

Kaken Pharmaceutical Co. Ltd., Annual General Meeting, Jun 27, 2014., at 10:00 Tokyo Standard Time. Location: Conference room, 17th Floor, Bunkyo Green Court. Agenda: To consider business report, consolidated an non-consolidated financial statements for the fiscal year ended March 31, 2014; to appoint appropriation surplus; to consider partial amendments to the articles of incorporation; to consider election of one director; to consider payment of bonuses to directors; and to consider other matters with regard to convocation of the general meeting of shareholders.

Kaken Pharmaceutical Co. Ltd. Reports Consolidated Earnings Results for the Year Ended March 31, 2014; Provides Earnings Guidance for the Six Months Ending September 30, 2014 and Year Ending March 31, 2015; Declares Dividend for the Year Ended March 31, 2014, Payable from June 30, 2014; Provides Dividend Guidance for the Fiscal Year 2014

Kaken Pharmaceutical Co. Ltd. reported consolidated earnings results for the year ended March 31, 2014. For the year, the company reported net sales of JPY 88,946 million, operating income of JPY 15,872 million, ordinary income of JPY 15,521 million and net income of JPY 9,735 million or JPY 114.14 per basic share as compared to net sales of JPY 87,054 million, operating income of JPY 14,611 million, ordinary income of JPY 14,250 million and net income of JPY 8,991 million or JPY 103.30 per basic share for the same period a year ago. Return on equity was 14.5% compared to 14.0% a year ago. Income before income taxes and minority interests was JPY 15,496 million compared to JPY 14,178 million a year ago. Net cash provided by operating activities was JPY 13,663 million compared to JPY 11,729 million a year ago. Purchase of property, plant and equipment was JPY 2,071 million compared to JPY 3,845 million a year ago. Purchase of intangible assets was JPY 55 million compared to JPY 69 million a year ago. The company provided earnings guidance for the six months ending September 30, 2014 and year ending March 31, 2015. For the six months ending September 30, 2014, the company expects net sales of JPY 44,200 million, operating income of JPY 7,900 million, ordinary income of JPY 7,700 million and net income of JPY 5,000 million or JPY 59.17 per basic share. For the year ending March 31, 2015, the company expects net sales of JPY 91,400 million, operating income of JPY 16,800 million, ordinary income of JPY 16,400 million and net income of JPY 10,700 million or JPY 126.63 per basic share. For the year ended March 31, 2014, the company declared a dividend of JPY 24.00 per share compared to JPY 22.00 per share paid a year ago. Scheduled date to commence dividends payment is June 30, 2014. For the six months ending September 30, 2014, the company expects to pay a dividend of JPY 27.00 per share compared to JPY 24.00 per share a year ago. For the year ending March 31, 2015, the company expects to pay dividend of JPY 27.00 per share compared to JPY 24.00 per share a year ago.

Kaken Pharmaceutical Co. Ltd., 2014 Earnings Call, May 13, 2014

Kaken Pharmaceutical Co. Ltd., 2014 Earnings Call, May 13, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4521:JP ¥2,157.00 JPY +11.00

4521 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4521.
View Industry Companies
 

Industry Analysis

4521

Industry Average

Valuation 4521 Industry Range
Price/Earnings 19.2x
Price/Sales 2.1x
Price/Book 2.7x
Price/Cash Flow 21.3x
TEV/Sales 2.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KAKEN PHARMACEUTICAL CO LTD, please visit www.kaken.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.